SCHEMBL1632102

SCHEMBL1632102

CS(=O)(=O)Nc1cc(C(c2cc(F)ccc2F)S(=O)(=O)c2ccc(Cl)cn2)c(Cl)cn1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 1/20 0.39
SCN1A P35498 6/20 0.39
SCN5A Q14524 6/20 0.39
SCN8A Q9UQD0 6/20 0.39
SCN9A Q15858 2/20 0.39
NR1I2 O75469 1/20 0.39
CYP2C9 P11712 1/20 0.39
SCN1B Q07699 1/20 0.39
SCN2A Q99250 1/20 0.39
PSEN1 P49768 5/20 0.39
PSEN2 P49810 5/20 0.39
APH1B Q8WW43 5/20 0.39
NCSTN Q92542 5/20 0.39
APH1A Q96BI3 5/20 0.39
PSENEN Q9NZ42 5/20 0.39
HTT P42858 1/20 0.37
TNF P01375 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
CCR2 P41597 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1632613 0.88 PSEN1 (0.51) ABL1SCN1ASCN5ASCN8ASCN9A
SCHEMBL1632633 0.87 PSEN1 (0.46) ABL1SCN1ASCN5ASCN8ASCN9A
SCHEMBL1633992 0.85 PSEN1 (0.42) ABL1SCN1ASCN5ASCN8ASCN9A
SCHEMBL1633173 0.82 PSEN1 (0.40) SCN1ASCN5ASCN8ASCN9ANR1I2
SCHEMBL1633292 0.81 PSEN1 (0.53) ABL1SCN1ASCN5ASCN8ASCN9A
SCHEMBL1633124 0.79 PSEN1 (0.50) ABL1SCN9APSEN1PSEN2APH1B
SCHEMBL1635319 0.77 PSEN1 (0.47) SCN1ASCN5ASCN8ASCN9ANR1I2
SCHEMBL1633359 0.77 ABL1 (0.40) ABL1SCN1ASCN5ASCN8ASCN9A
SCHEMBL1631232 0.76 SCN1A (0.41) SCN1ASCN5ASCN8ANR1I2SCN1B
SCHEMBL12724228 0.76 HTT (0.37) ABL1SCN1ASCN5ASCN8APSEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US claimed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-7932271-B2 Heterocyclic methyl sulfone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2011-04-26 US disclosed
US-20060241302-A1 Morpholine derivatives DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-10-26 US disclosed
EP-1640366-A1 HETEROCYCLIC METHYL SULFONE DERIVATIVE DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060241302-A1 Morpholine derivatives APP, BACE1, SMS ABL1 3362/4885SCN1A 41/4885SCN5A 83/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.